GuidelineEuropean journal of nuclear medicine and molecular imaging2013
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.
Guideline in European journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04790708 (Peptide Receptor Radionuclide Therapy), which is not on this map. Cited by 338 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors
Who cites it
338 citing papers in PubMed, 3 syntheses or guidelines pooled it, 798 citations in OpenAlex.
- Radioligand therapy for primary brain tumors: a PRISMA-based systematic review of meningiomas and gliomas.Frontiers in medicine · 2025Pooled it
- Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0.European journal of nuclear medicine and molecular imaging · 2024Guideline
- The therapeutic efficacy of 177Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis.Medicine · 2020Pooled it
- Dosimetry and pharmacokinetics of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Efficacy ofCurrent oncology (Toronto, Ont.) · 2020Trial
- A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma.European journal of nuclear medicine and molecular imaging · 2020Trial
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes withEuropean journal of nuclear medicine and molecular imaging · 2020Trial
- Cholecystokinin 2 Receptor AgonistJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
- Application of theranostics in thyroid cancer management.The Journal of clinical endocrinology and metabolism · 2026Review
- Article
- Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Evolutionary landscape and collaborative networks of global theranostic research in nuclear medicine: a visual bibliometric analysis.Nuclear medicine communications · 2026Article
- Comparative assessment of KDIGO and CTCAE criteria for detecting renal function deterioration after peptide receptor radionuclide therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- [EClinicalMedicine · 2026Article
- Optimization of Gravity Infusion Protocols forPharmaceutics · 2026Article
- Estimation of split renal function on PET using the SSTR-targeting radioligands [European journal of nuclear medicine and molecular imaging · 2026Article
- Pancreatic Neuroendocrine Tumor in Lynch Syndrome: Expanding the Tumor Spectrum of Mismatch Repair Deficiency.Cureus · 2026Article
- Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.European journal of nuclear medicine and molecular imaging · 2026Review
- Comparing Response Evaluation Methods for PRRT in Neuroendocrine Tumors: Insights from an Exploratory Study.Cancers · 2026Article
- Radioligand Therapy and Sequencing in Gastroenteropancreatic Neuroendocrine Tumors: A Patient Perspective Review.JCO oncology practice · 2026Review
278 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issuedO'Dorisiol, T M [corrected to O’Dorisio, T M]
Authors and funding
12 authors at 6 institutions in 6 countries.
Funding
Abstract
Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy involving the systemic administration of a radiolabelled peptide designed to target with high affinity and specificity receptors overexpressed on tumours. PRRNT employing the radiotagged somatostatin receptor agonists (90)Y-DOTATOC ([(90)Y-DOTA(0),Tyr(3)]-octreotide) or (177)Lu-DOTATATE ([(177)Lu-DOTA(0),Tyr(3),Thr(8)]-octreotide or [(177)Lu-DOTA(0),Tyr(3)]-octreotate) have been successfully used for the past 15 years to target metastatic or inoperable neuroendocrine tumours expressing the somatostatin receptor subtype 2. Accumulated evidence from clinical experience indicates that these tumours can be subjected to a high absorbed dose which leads to partial or complete objective responses in up to 30 % of treated patients. Survival analyses indicate that patients presenting with high tumour receptor expression at study entry and receiving (177)Lu-DOTATATE or (90)Y-DOTATOC treatment show significantly higher objective responses, leading to longer survival and improved quality of life. Side effects of PRRNT are typically seen in the kidneys and bone marrow. These, however, are usually mild provided adequate protective measures are undertaken. Despite the large body of evidence regarding efficacy and clinical safety, PRRNT is still considered an investigational treatment and its implementation must comply with national legislation, and ethical guidelines concerning human therapeutic investigations. This guidance was formulated based on recent literature and leading experts' opinions. It covers the rationale, indications and contraindications for PRRNT, assessment of treatment response and patient follow-up. This document is aimed at guiding nuclear medicine specialists in selecting likely candidates to receive PRRNT and to deliver the treatment in a safe and effective manner. This document is largely based on the book published through a joint international effort under the auspices of the Nuclear Medicine Section of the International Atomic Energy Agency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.